The S&P/ASX 200 Health Care Index (ASX: XHJ) is the worst performing sector by far in 2026 and has significantly unperformed the broader index. The decrease has pushed many major ASX healthcare companies to multi-year lows.

At the time of writing, the ASX 200 Health Care Index is down around 34% for the year to date and 47% lower than 12 months ago.

For context, the wider S&P/ASX 200 Index (ASX: XJO) is largely flat for the year to date and 3% higher than this time last year.

Sector wide declines might look concerning, but I think it presents a great opportunity for investors to buy into ASX 200 healthcare shares for cheap.

Here are three stocks that I'd buy today, while they're on sale.

ResMed Inc (ASX: RMD)

ResMed shares have fallen to a two-year low this week and are down 28% for the year so far. The global leader in sleep health was swept up in the general sector-wide ASX healthcare sell-off. Its latest third-quarter earnings update also came in softer than expected, which didn't help lessen declining sentiment. But I think the ASX 200 healthcare share is now oversold and below fair value. Sleep disorders require long-term management, and as a global leader, ResMed has a powerful position in a large (and growing) market. According to Market Index data, brokers have a strong buy consensus on ResMed shares and tip a 67% upside to an average $43.38 target price, at the time of writing.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel shares have rebounded around 14% since hitting a two-year low in mid-May, but the shares have still got some more room to run before they return to 2025-levels. At the time of writing, the shares are still down around 6% for the year to date and they're 11% lower than 12 months ago. Investors have been buying this medical device company's shares following the release of its strong FY26 result last month, which showed investors that the business is sound. The ASX 200 healthcare company reported a 14% increase in total operating revenue and a 24% increase in NPAT. Brokers rate the shares as a strong buy and tip a potential 21% upside to an average $36.90 target price, at the time of writing.

Pro Medicus Ltd (ASX: PME)

Pro Medicus shares have rebounded around 21% since the health imaging technology company announced a new contract win. In late May, the ASX 200 healthcare company confirmed it has signed a five-year, A$28 million contract renewal with Allegheny Health Network (AHN). The increase has helped recoup some, but not all losses shed by the company over the past year. Pro Medics shares are still around 28% lower for the year to date and 43% below their trading price this time last year. The company's US subsidiary also won two $40 million five-year contract renewals back in early March. It looks like we'll see plenty more out of the company over the next 12 months, too. The majority of brokers rate the ASX 200 healthcare shares as a strong buy and tip an 18% upside to an average $188.51 target price, at the time of writing.

The post 3 ASX 200 healthcare shares to buy while they're on sale appeared first on The Motley Fool Australia.

A small group of ASX shares have ex-dividend dates this month.

In order to receive a dividend, you must own the ASX share before its ex-dividend date.

So, if you're looking for some extra income before the end of the financial year (EOFY), these ASX shares provide options.

Ex-dividend dates also provide another opportunity.

Share prices usually fall on ex-dividend dates, so you may be able to pick up a stock you've been watching for a lower price.

Among the shares going ex-dividend this month are ASX agriculture stock Select Harvests Ltd (ASX: SHV).

The almond producer will trade ex-dividend on 17 June and pay investors 3.5 cents per share on 15 July.

Bell Potter has a buy rating on Select Harvests shares with a 12-month price target of $5.30, compared with $3.86 currently.

ASX 200 iron ore share Champion Iron Ltd (ASX: CIA) has an ex-dividend date of 11 June and will pay 2 cents per share on 8 July.

RBC Capital has a buy rating on Champion Iron with an $8.11 target, compared to $4.30 per share today.

Several of Wilson Asset Management's listed investment companies (LICs) will also go ex-dividend this month.

These include WCM Global Growth Ltd (ASX: WQG), which will trade ex-dividend on 10 June.

WCM Global Growth investors will receive a dividend of 2.2 cents per share on 30 June.

ASX shares with ex-dividend dates in June

The post 15 ASX shares going ex-dividend before EOFY appeared first on The Motley Fool Australia.

After some morning wobbles, the ASX 200 spent most of the session in green territory, and ended up closing with a happy 0.69% rise. That leaves the index at 8,717.7 points.

This pleasant Wednesday session for Australian investors comes after a mixed return to trading for the American markets last night, following Monday's public holiday.

The Dow Jones Industrial Average Index (DJX: .DJI) gave up some initial optimism to close down 0.23%.

However, the tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) fared better, gaining a solid 1.19%.

But let's return to the local markets now and look a little closer at what was happening with the different ASX sectors this hump day.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

After kicking off the trading week on a positive note yesterday, investors couldn't keep up the momentum, with the index opening in the red this morning and staying that way all session. By the time the markets closed up shop, the ASX 200 had lost 0.39% and finished up at 8,657.8 points.

The US markets were closed for the Memorial Day public holiday last night, so the small gains we saw 'Stateside last Friday are still holding.

So, without further ado, it's now time to take stock of how the various ASX sectors fared amid today's frosty trading conditions.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back today are listed below. Here's why they are rising:

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

The Fisher & Paykel Healthcare share price is up 7% to $29.66. Investors have been buying this medical device company's shares following the release of a strong FY 2026 result. Fisher & Paykel Healthcare reported a 14% increase in total operating revenue to NZ$2.31 billion and a 24% increase in net profit after tax to NZ$469.5 million for FY 2026. The company's CEO, Lewis Gradon, said: "Our Hospital business performed strongly across the portfolio of therapies globally. We were especially encouraged by consumables growth, given it occurred during a period in which hospital admissions for seasonal respiratory illnesses in the United States and other major markets appeared to be subdued compared to the previous year. This suggests that changing clinical practice continues to be a strong growth driver."

GR Engineering Services Ltd (ASX: GNG)

The GR Engineering Services share price is up 5.5% to $5.50. This morning, this engineering services company won an engineering, procurement and construction (EPC) contract from Boab Metals Ltd (ASX: BML). This is in relation to the Sorby Hills Silver-Lead Project, which is located 50 km from Kununurra in Western Australia. The company estimates that the contract is worth $109 million.

Kogan.com Ltd (ASX: KGN)

The Kogan share price is up 16% to $3.99. The catalyst for this has been the release of a trading update from the ecommerce company this morning. For the 10 months ended 30 April, Kogan reported total gross sales growth of 13.2% to $875.6 million and a 25.4% increase in group adjusted EBIT to $26.9 million. This was driven by a strong performance from the core Kogan business and a much-improved performance from the Mighty Ape business. It said: "The Company delivered a Group Adjusted EBITDA margin of 8.6%, towards the upper end of previously provided FY26 guidance, which includes the impact of the turnaround of Mighty Ape. This performance was driven by strong profitability within Kogan.com, which achieved Adjusted EBITDA margin of 11.5%, together with materially improved performance at Mighty Ape in the most recent four months to 30 April 2026."

Wesfarmers Ltd (ASX: WES)

The Wesfarmers share price is up almost 2% to $77.14. This may have been driven by a broker note out of Morgans. It has upgraded the Bunnings owner's shares to an accumulate rating (from trim) with a slightly improved price target of $81.10 (from $80.50). It said: "WES's share price has fallen 9% over the past 12 months and 7% over the past 6 months. The stock is now trading on a more reasonable 26.5x FY27F PE compared to a peak one-year forward multiple of ~37x in August 2025."

The post Why Fisher & Paykel Healthcare, GR Engineering, Kogan, and Wesfarmers shares are pushing higher appeared first on The Motley Fool Australia.

In morning trade, the ASX 200 stock is up 9% to $30.07.

This follows the release of the medical device company's FY 2026 results before the market open.

ASX 200 stock jumps on results day

For the 12 months ended 31 March, Fisher & Paykel Healthcare reported a 14% increase in total operating revenue to NZ$2.31 billion.

A key driver of this was its Hospital Products segment, which includes products used in respiratory, acute and surgical care. This side of the business reported revenue of NZ$1.51 billion, which is up 18% on the prior corresponding period. Sales of hospital consumables were up 16% over the prior financial year.

Commenting on the performance of its Hospital Products segment, the company's managing director and CEO, Lewis Gradon, said:

Our Hospital business performed strongly across the portfolio of therapies globally. We were especially encouraged by consumables growth, given it occurred during a period in which hospital admissions for seasonal respiratory illnesses in the United States and other major markets appeared to be subdued compared to the previous year. This suggests that changing clinical practice continues to be a strong growth driver.

The ASX 200 stock's Homecare Products segment, which includes products used in the treatment of obstructive sleep apnoea (OSA) and respiratory support in the home, delivered revenue of NZ$802.7 million. This was an 8% increase over the prior corresponding period. OSA masks revenue was up 7% for the full year.

Gradon commented:

Our latest mask ranges, the F&P Solo and F&P Nova, continued to drive OSA mask growth. Our newest offering, the F&P Nova Nasal, was launched in the United States this past January to a positive reception.

Fisher & Paykel Healthcare revealed that its gross margin improved to 63.7% during the year. This is an increase of 80 basis points or 122 basis points in constant currency. Management advised that this reflects the ongoing progress of its continuous improvement initiatives. It also includes the approximately 90-basis-point impact in constant currency of US tariffs on hospital products sourced from New Zealand.

This ultimately led to the ASX 200 stock delivering a 24% increase in net profit after tax to NZ$469.5 million for FY 2026.

Outlook

Management is expecting further growth in FY 2027.

It has provided guidance of FY 2027 operating revenue in the range of approximately NZ$2.45 billion to NZ$2.57 billion, and net profit after tax of NZ$500 million to NZ$550 million. This represents annual growth of 6% to 11% and 4.3% to 14.7%, respectively.

It notes that this guidance includes an estimated 50-basis point net impact to its gross margin from US tariffs and the Middle East conflict.

Commenting on its outlook, Gradon said:

The growth we have achieved is uncommon, and we do not take it for granted. The key now is to sustain that momentum – continuing to innovate, improve and work closely with our customers to create lasting value.

Our products and therapies supported the care of around 24 million patients last year. This impact reflects the efforts of many thousands of people working toward a common purpose of improving outcomes. We want to acknowledge the people of Fisher & Paykel Healthcare for their commitment, and we also want to thank our clinical partners, customers, suppliers and shareholders.

The post Guess which ASX 200 stock is jumping 9% on FY26 results appeared first on The Motley Fool Australia.

The rebound is happening across most of the sectors on the ASX All Ords Index, and it's positive news for the companies that slumped to 52-week lows on Monday.

Here are four ASX All Ords shares rebounding from a dip today. Here's what brokers expect next.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel Healthcare shares have rebounded 2.06% on Tuesday to $27.21, at the time of writing. It's a welcome turnaround after the ASX All Ords healthcare stock crashed to a two-year low of just $26.67 on Monday. Overall, healthcare shares have come under pressure so far in 2026, and stock prices have tumbled across the board. Slumping sentiment has been driven by a weaker US dollar, concerns about more interest rate rises, rising inflation, and cost-of-living pressures. There are also ongoing concerns about tariffs. But the business remains relatively sound. And the respiratory designer and manufacturer still expects to meet its revised FY26 revenue and profit guidance figures. Brokers rate the ASX All Ords stock as a strong buy and tip a potential 29% upside to $35.10, at the time of writing. 

Endeavour Group Ltd (ASX: EDV)

Endeavour shares have rebounded 2.48% higher to $3.10, at the time of writing. At the close of the ASX on Monday, the shares had crashed to an all-time low of $3.02. The alcoholic beverages retailer, hotel operator, and poker machines operator, owns major retail drinks companies such as Dan Murphy's and BWS. It also owns other brand names such as ALH Hotels, Langton's, and Jimmy Brings. Weaker consumer sentiment has hit the company's growth recently, while higher supply-chain costs and inflation have put margins under pressure. But Endeavour is investing heavily in market competitiveness and online growth. Although brokers aren't sure if the ASX All Ords company can pull off a turnaround. They rate the cost as a sell and top a 12-month target price of $3.51. However, after the latest price crash, it still represents a 14% upside at the time of writing.

Orora Ltd (ASX: ORA)

The packaging company's shares are also rebounding 0.8% at the time of writing, to $1.26. The update comes after the shares crashed to an all-time low on Monday. The ASX All Ords company's share price crashed 18% in early April following its latest trading update. Investors jumped on their sell buttons after the company downgraded its full-year FY26 EBIT guidance for its Saverglass division, citing disruptions from conflict in the Middle East. Brokers are also cautious about the company's outlook. They rate the stock a hold and tip a potential 34% upside to $1.71 at the time of writing. 

Tabcorp Holdings Ltd (ASX: TAH)

Tabcorp shares are climbing higher on Tuesday. At the time of writing, the shares are 1.78% higher at 69 cents a piece. The turnaround follows a slump to a 52-week low yesterday. The wagering company's shares have come under pressure since late 2023 following weaker revenue and profit performance. The stock was gaining traction in early 2026, but news of a letter from Australia's financial crimes watchdog, AUSTRAC, earlier this month sent the share price crashing. The ASX All Ords company said that the watchdog raised serious concerns about the company's ability to identify, mitigate, and manage money laundering and terrorism financing risks. It has also started an enforcement investigation. The shares have lost 41% of their value since the announcement. And brokers are reserved about their outlook for the company. They rate the stock as a hold and tip a potential 42% upside to 98 cents, at the time of writing. 

The post Are these 4 ASX All Ords stocks a buy after rebounding from 52-week lows? appeared first on The Motley Fool Australia.

At the time of writing, the shares are $26.99 each.

The latest sell-off means the shares have now tumbled 22% from a 52-week peak recorded in February this year. They're also 21% below trading levels seen this time last year.

Here's what happened, and what to expect out of the ASX 200 healthcare stock next.

Why are the ASX 200 healthcare shares tumbling?

Overall, the ASX 200 healthcare index has come under pressure so far in 2026, and shares are tumbling across the board.

The ASX 200 healthcare index has tumbled 32% for the year-to-date and is 45% lower than 12 months ago. Several sector giants hit multi-year lows over the past couple of weeks.

The sector is now the worst performer of the 11 market sectors, driven by a weaker US dollar, concerns about more interest rate rises, rising inflation, cost-of-living pressures and slumping sentiment.

There are also ongoing concerns about tariffs and general global economic uncertainty which are affecting margins and export earnings of major players like Fisher & Paykel Healthcare which generate substantial revenue overseas.

The company is facing specific company headwinds too.

There are some concerns that Fisher & Paykel Healthcare shares are overvalued relative to their earnings, even after the latest pullback.

It's also possible that the shares have dipped ahead of the company's full-year results announcement later this month.

Despite tumbling sentiment and a weakening share price, as a business Fisher & Paykel Healthcare remains relatively sound. 

The respiratory designer and manufacturer raised its FY26 revenue and profit guidance in February. 

The company expects its full-year FY26 operating revenue will be around $2.30 billion (previously $2.17–$2.27 billion) and NPAT will be between $450 million and $470 million (previously $410 million–$460 million). Guidance assumes NZ:US exchange rate of 60 cents as at 31 January 2026.

Is this an opportunity for investors to buy in the dip, or is there more downside to come?

It looks like the latest dip could be a good opportunity for investors to buy into the ASX 200 healthcare stock for cheap.

TradingView data shows that eight out of 18 analysts have a buy or strong buy rating on Fisher & Paykel Healthcare's shares. Another eight have a hold rating and two rate the stock as a sell or strong sell.

The average $33.81 target price implies a potential 25% upside over the next 12 months, at the time of writing. Others think the shares could storm 57% higher to $42.40 a piece. 

The post This ASX 200 healthcare stock has crashed to a multi-year low: Here's why and what's next appeared first on The Motley Fool Australia.

This makes healthcare the worst performer of the 11 market sectors over the past 12 months.

It's even worse than technology, which is down 26% on fears that artificial intelligence (AI) is an existential threat to the sector.

However, while technology is turning around, healthcare remains in the doldrums.

The S&P/ASX 200 Health Care Index (ASX: XHJ) hit a six-year low of 25,193 points today.

What's going on?

Expert explains multiple headwinds hitting healthcare

Samy Sriram, a market analyst at online investment platform, Stake, says there are multiple reasons for healthcare's downward spiral.

First of all, there are currency headwinds and the likelihood of further interest rate rises in Australia.

Sriram said:

A weaker US dollar is eroding the offshore profits of giants like CSL Ltd (ASX: CSL), which accounts for 45% of the index.

At the same time, the RBA's decision to keep interest rates high to fight inflation is weighing heavily on the valuations of growth stocks like Pro Medicus Ltd (ASX: PME).

The Australian dollar is currently at a four-year high of 71.3 US cents, up 12% over 12 months.

Meanwhile, the Reserve Bank has already raised interest rates twice this year, and the market is pricing in a 76% chance of another hike next Tuesday.

Cost-of-living pressures force patients to compromise

Sriram also says cost-of-living pressures are impacting healthcare companies, not only in Australia, but also overseas.

She commented:

… persistent cost of living pressures in the US are alarmingly turning some medical procedures into optional expenses.

We've seen this with Cochlear Ltd (ASX: COH), an Australian company that manufactures and supplies hearing aids.

Their shares tumbled 35% due to patients deferring implants.

Last week, Cochlear downgraded its FY26 earnings guidance substantially.

The company now expects an FY26 underlying net profit of $290 million to $300 million, down from $435 million to $460 million.

Management commented:

Consumer sentiment has declined in key markets, reaching historic lows in the US.

The decline appears to be affecting discretionary healthcare decisions in the adults and seniors segment, adding to demand uncertainty in the near term.  

In Australia, consumer sentiment experienced its biggest fall in five years this month.

Iran war's impact on healthcare

The International Monetary Fund (IMF) has warned of a global recession as the fuel crisis drags on, with no end to the war in sight.

A recession would further erode consumer confidence due to inevitable job losses.

For now, Sriram said the war in Iran was hitting healthcare through higher shipping costs.

She commented:

With hospital operators like Ramsay Health Care Ltd (ASX: RHC) already being squeezed by rising staff wages and capped insurance payouts, geopolitical volatility is putting extra strain on the books, despite having a turnaround in 2026.

(Ramsay Health Care shares hit an 18-month high of $44.73 in March. The ASX 200 healthcare share is up 21% over six months.)

Cochlear also discussed shipping issues and capped insurance payouts last week.

Cochlear said it expects "order cancellations and a heightened risk of delivery delays to some countries" due to instability in the Middle East, and that lower reimbursements to patients in China "will lower premium tier sales in China in the second half".

FDA uncertainty under Trump

Biotech investors are also growing wary of the US Food and Drug Administration (FDA) under the Trump administration.

Leadership upheaval at the FDA, along with conflicting signals on approval standards across different categories of foods and medicines, has created uncertainty over how, and whether, new drugs and products will reach the market.

Earlier this month, a rare diseases advocacy group wrote to President Donald Trump and Health Secretary Robert F. Kennedy Jr., citing reduced flexibility at the FDA and a large proportion of biotech firms reporting difficulty raising funding.

Meanwhile, Secretary Kennedy has openly promoted vaccine scepticism and disputed scientific claims amid a global trend in fewer people seeking vaccinations, possibly as a reaction to mandatory programs and COVID-vaccine injuries during the pandemic.

At CSL's 2025 AGM, former CSL CEO Dr Paul McKenzie commented: "… we have seen a greater decline in influenza vaccination rates in the U.S. than we expected."

Last week, The Australian reported that the US military has now scrapped its annual flu shot requirement for service members.

Foolish Takeaway

All of these factors are hitting the healthcare sector hard, and sending many ASX 200 healthcare shares to multi-year low prices.

Here's how the top 10 ASX 200 healthcare shares by market capitalisation have performed over the past 12 months.

The post What's making healthcare the worst sector on the ASX 200, down 39% in a year? appeared first on The Motley Fool Australia.

The Australian share market has seen widespread selling across most sectors and weak investor sentiment. The ASX 200 is also reacting to a mixed start in US sharemarkets this week.

The softer market has also seen some ASX 200 shares fall to fresh 52-week lows.

Here are four of them.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel shares are down another 0.24% this morning to a new 52-week low of $29.18 a piece. The slump means the respiratory designer and manufacturer's share price is now 10% lower year to date and 9% lower than this time last year. There hasn't been any price-sensitive news out of the company recently to explain the decline, so it's most likely the result of a continued sector-wide sell-off of ASX healthcare shares. TradingView data suggests brokers are still bullish for the ASX 200 company's shares, with the majority holding a buy or strong buy rating on the stock. Brokers tip an average 20% upside to $34.86 over the next 12 months.

Ansell Ltd (ASX: ANN)

Ansell is another ASX 200 healthcare company that makes gloves and other personal protection equipment. Its shares have also been caught up in the widespread ASX healthcare sell-off. At the time of writing, Ansell shares are down 1.06% to $26.24 a piece, marking a 22-month low. Again, brokers are bullish about the outlook for the ASX 200 company's shares. Out of 12 analysts, seven have a hold rating and 5 rate the shares a buy or strong buy. Brokers tip an average 34% upside to $35.18 over the next 12 months. Some think the shares can rocket even further. The maximum $40.45 target price implies a potential 54% upside at the time of writing.

Harvey Norman Holdings Ltd (ASX: HVN)

Harvey Norman shares have hit a fresh 52-week low of $4.47 in Tuesday morning trade. The share price has now crashed 36% for the year to date after the sell-off accelerated in late February. The ASX 200 retail giant has faced strong headwinds over the past year on the back of renewed concerns about rising inflation and how it could impact consumer spending. Tighter household budgets mean Australians are spending less on discretionary items this year. At the same time, after a strong rally in mid-late 2025, it looks like investors quickly took their profits off the table in early 2026. TradingView data shows that analysts are relatively divided about the outlook for the shares, with several neutral ratings, but they mostly agree that the shares are now trading below fair value. The average target price on the ASX 200 retail shares is $5.76, which implies another 29% upside at the time of writing. 

Metcash Ltd (ASX: MTS)

Metcash shares have tumbled another 1.42% in morning trade to a new 52-week low of $2.78 a piece. It also represents the lowest point the shares have fallen to in nearly six years. The IGA network owner's shares have come under pressure following an underwhelming FY26 half-year result in December last year. It continues to face headwinds amid a tough retail environment and dwindling demand in its tobacco and liquor businesses. Analysts are mostly neutral on the outlook for the shares, but they do all agree that there will be some level of upside ahead. The average target price of $3.44 implies a potential 23% upside over the next 12 months, at the time of writing. 

The post These 4 ASX 200 shares have slumped to fresh 52-week lows: Buy, sell or hold? appeared first on The Motley Fool Australia.

What did Fisher & Paykel Healthcare report?

• Full-year FY26 operating revenue now expected to be around $2.30 billion (previously $2.17–$2.27 billion)
• Net profit after tax (NPAT) raised to between $450 million and $470 million (previously $410 million–$460 million)
• Guidance assumes NZ:US exchange rate of 60 cents as at 31 January 2026
• Updated figures do not include any potential US tariff refunds

What else do investors need to know?

Fisher & Paykel Healthcare reported strong growth across its full range of Hospital products, contributing to the upgraded guidance. The company noted ongoing improvements in gross margin and operating margin, supported by efficiency gains and continuous improvement activities.

A major regulatory update came as the United States Supreme Court overturned tariffs imposed under the IEEPA, but Fisher & Paykel Healthcare continues to work through the refund process and potential implications. Management expects to provide a further update on any tariff impacts with the full-year results in May.

What did Fisher & Paykel Healthcare management say?

Managing Director and CEO Lewis Gradon said:

We have continued to see good growth across the full range of our Hospital products so far during our second half.

Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.

What's next for Fisher & Paykel Healthcare?

Looking ahead, management will provide more detail on tariff developments and possible refunds when announcing its full-year results. The company remains confident that cost increases from tariffs will be mitigated over time by ongoing efficiency efforts.

Fisher & Paykel Healthcare continues to focus on innovation, expanding its footprint in respiratory care, and driving sustainable, profitable growth. The company maintains that the long-term strategy and direction are unchanged.

Fisher & Paykel Healthcare share price snapshot

Over the past 12 months, Fisher & Paykel shares have risen 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Fisher & Paykel Healthcare upgrades FY26 earnings outlook appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

At the time of writing, Fisher & Paykel shares were trading at $34.52 on the ASX and up 8% for the day.

The market's response was in appreciation of the broad-based strength across both the Hospital and Homecare divisions, as well as an upgrade to full-year guidance.

What did Fisher & Paykel report?

Fisher & Paykel posted operating revenue of $1.09 billion for the six months to 30 September 2025, an increase of 14% on the same period last year, or 12% in constant currency. Net profit after tax rose sharply to $213 million, up 39%, reflecting strong demand for the company's respiratory care products and the benefits of operational efficiencies.

The hospital division was the standout contributor. Revenue in this segment reached $692.2 million, up 17%, driven by broad-based strength across the consumables portfolio and a particularly strong lift in hardware sales, which grew 21% in constant currency. Notably, this momentum came despite a relatively mild respiratory season, underscoring the structural shift toward high-flow therapy and non-invasive ventilation across global hospitals.

Homecare also delivered steady growth, with revenue rising to $395.9 million, an increase of 10%. The company highlighted robust uptake of its newest obstructive sleep apnea (OSA) masks (including the Nova Nasal and Nova Micro), which are now available across several major markets. These products contributed to an 8% constant-currency lift in OSA mask revenue.

Margins improved materially during the half. Gross margin expanded to 63%, up 110 basis points year on year. Even after accounting for the drag from US tariffs on New Zealand-sourced hospital products, margin gains were supported by continuous improvement initiatives and efficiency gains across the business. Operating profit rose 31%, lifting the operating margin to 26.3%.

The board increased the interim dividend to 19 cents per share, fully imputed and payable on 16 December 2025.

Outlook

In addition to the result, FPH upgraded its full-year outlook. At prevailing exchange rates as of 31 October, the company now expects revenue of $2.17 billion to $2.27 billion (previous guidance provided in August was for revenue of $2.15billion to $2.25billion) and net profit of $410 million to $460 million (previous guidance provided in August was $390m to $440m).

Management noted that last year's Northern Hemisphere winter was unusually strong for respiratory hospitalisations. Should the upcoming season follow a similar pattern, performance is likely to land toward the higher end of guidance.

Despite the improved earnings outlook, the company emphasised that full-year margins will continue to reflect the impact of US tariffs, which are expected to reduce gross margin by around 75 basis points. Even so, Fisher & Paykel believes its operational efficiency initiatives will continue to offset part of this drag.

Foolish bottom line

Fisher & Paykel Healthcare delivered the combination of growth, margin expansion, and upgraded guidance that investors look for in a high-quality medical technology company. The strength in hospital consumables (even during a softer clinical season) suggests the company's products are becoming increasingly embedded in global care pathways. Homecare continues to provide a solid second engine of growth, supported by an expanding pipeline of OSA mask innovations.

The result reinforces FPH's long-term ambition to sustainably double its constant-currency revenue every five to six years. With clinical adoption rising, a refreshed product portfolio gaining traction, and operational efficiency improving, the market's positive reaction reflects growing confidence that the company is back on a clear upward trajectory.

The post Fisher & Paykel shares surge 8% on half-year results appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

But that was just the warm-up.

In the weeks ahead, dozens of ASX-listed companies across all sectors will deliver their outcomes for the full financial year, or for the six-month period ending in June.

And that includes some of the biggest and most closely watched ASX 200 healthcare stocks.

Kicking off proceedings was Resmed CDI (ASX: RMD) – a specialist in sleep disorder treatment – with Friday's fourth quarter and full year results.

In brief, the group's FY25 revenue jumped by 10% from a year ago, which helped to fuel a 19% increase in operating profit.

The market appeared to respond favourably, with the company's share price lifting by 1% from Thursday's close to hit record highs in Friday's trading.

ResMed's share price has now risen by 16% since the start of the year, ending last week at $42.88 per share.

In comparison, the All Ordinaries Index (ASX: XAO) is up by 5.3% over the same period.

But how will the rest of the healthcare sector perform during reporting season?

Watch this space

The list below presents 10 ASX 200 healthcare stocks set to report in August.

But before diving in, there's a few important notes to consider.

Firstly, some of these dates may change as companies conclude their number crunching.

In addition, this is not a complete list. More healthcare businesses will also be revealing their results in the coming weeks.

And one final thing.

For investors tracking other sectors, reporting dates for ten leading ASX 200 mining stocks can be found here.

Similarly, a schedule for six prominent ASX 200 energy stocks is located here.

FY25 reporting dates – ASX 200 healthcare stocks

• Thursday 14 August – Pro Medicus Ltd (ASX: PME): This imaging software provider gets the ball rolling.
• Friday 15 August – Cochlear Ltd (ASX: COH): An iconic Aussie business specialising in implantable hearing solutions.
• Tuesday 19 August – CSL Ltd (ASX: CSL): The healthcare sector's biggest company and third largest on the ASX.
• Friday 22 August – A four-company event:
  • Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH): Manufacturer of respiratory care products.
  • Healius Ltd (ASX: HLS): Diagnostic services provider.
  • Telix Pharmaceuticals Ltd (ASX: TLX): Growing diagnostic radiopharmaceuticals business.
  • Sonic Healthcare Ltd (ASX: SHL): Diversified healthcare provider.
• Monday 25 August – A double announcement:
  • Ansell Ltd (ASX: ANN): Protective personal equipment manufacturer.
  • Polynovo Ltd (ASX: PNV): Medical device developer.
• Thursday 28 August – Ramsay Health Care Ltd Fully Paid Ord. Shrs (ASX: RHC): Owner and operator of hospitals and health care clinics across 11 countries.

The post CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August appeared first on The Motley Fool Australia.

The S&P/ASX 200 Index (ASX: XJO) had a great start to the new financial year, rising 1.04% over the week to finish at 8,603 points.

Healthcare was partly propelled by a 9.73% surge for the unstoppable sector darling Pro Medicus Ltd (ASX: PME) shares.

For the first time ever, the Pro Medicus share price cracked the $300 mark last week, closing at $307.89 per share on Friday.

The stock set a new record at $316.47 on Thursday after the company announced two major contracts in the US.

Pro Medicus is now one of only two ASX 200 healthcare shares with a share price above $300.

The other is Cochlear Ltd (ASX: COH) shares.

What does Pro Medicus do?

As my colleague James explains, Pro Medicus has become a key player in the digitisation of global healthcare.

The company provides cloud-based radiology software to major hospital networks across the US, Europe, and Australia.

With high margins, zero debt, and a sticky client base, Pro Medicus continues to attract new contracts and report strong earnings growth.

Runaway momentum on Pro Medicus shares

Another colleague, Bernd, points out that we all could have invested in Pro Medicus shares for about $42 apiece just three years ago.

Let that painful truth sink in for a moment.

That is 625% share price growth.

Here is a visual aid.

In FY25, the Pro Medicus share price rose 99% to close at $285 per share on 30 June.

Pro Medicus was the second-best performer of the ASX 200 healthcare sector in FY25.

It was beaten by Sigma Healthcare Ltd (ASX: SIG) shares, which rose by 135% after the blockbuster Chemist Warehouse merger.

The S&P/ASX 200 Health Care Index (ASX: XHJ) declined in FY25, losing 6% in value.

Where to from here for Pro Medicus shares?

Morgan Stanley and Bell Potter think Pro Medicus shares don't have much more room to grow.

Morgan Stanley has an overweight rating and a 12-month price target of $310 on Pro Medicus shares.

Last week, Bell Potter downgraded Pro Medicus from a buy to a hold rating with an improved price target of $320, up from $280.

What else happened with ASX 200 healthcare shares last week?

Among the other ASX 200 healthcare sector heavyweights, CSL Ltd (ASX: CSL) shares lifted 3.59% to close at $242.76 on Friday.

Sigma shares gained 2.03% to close at $3.01 apiece.

The share price of private healthcare provider and hospital owner Ramsay Health Care Ltd (ASX: RHC) ripped 8.8% to $39.30.

The Cochlear Ltd (ASX: COH) share price rose 1.88% to $300.99.

Shares in pathology provider Sonic Healthcare Ltd (ASX: SHL) lifted 1.72% to close at $27.16 on Friday.

Resmed CDI (ASX: RMD) shares lifted 1.16% to $39.40 per share.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares lifted 0.33% to $33.82 apiece.

Among the small-cap healthcare shares, Clarity Pharmaceuticals Ltd (ASX: CU6) rose 16.67% to close at $2.94 on Friday.

ASX 200 market sector snapshot

Here's how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

The post Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors appeared first on The Motley Fool Australia.

During this time, the medical device company's shares have risen almost 30%.

This left them trading at $34.84 at Monday's close, which is just a fraction short of a record high.

Is it too late to invest? Let's see what Macquarie Group Ltd (ASX: MQG) is saying about the company.

What is Macquarie saying about Fisher & Paykel Healthcare?

According to a note out of the investment bank, the broker was impressed with the company's performance during FY 2025. Though, it concedes that its outlook was softer than it was expecting.

Commenting on its results, the broker said:

Hospital revenue was 2% ahead of our forecasts, driven by better-than-expected new apps revenue (+2% vs MRE, +18% CC YoY) and hardware sales (+5% vs MRE, +15% CC YoY). Management highlighted broad-based strength across the entire portfolio supported by ongoing change in clinical practice and a strong seasonal hospitalisation census. Management indicate top-end of guidance would achieve "a little bit above 12%" growth for hospital revenue, with seasonal respiratory hospitalisation rate and intensity driving demand variability (MRE ~9% CC).

Homecare revenue (+11% CC YoY) was largely in line with our forecast. Management highlighted strong contributions from new OSA masks including the Solo (launched in the US in Apr-24) and the Nova (launched in the US in Nov-24). However, CC growth declined from 14% in 1H25 to 9% in 2H25 due to competitor launches. Management expects FY26 growth to be similar to 2H25 (MRE ~8% CC).

And while it was disappointed with its guidance for FY 2026, Macquarie was pleased to see that management is guiding to better than expected margins over the medium term. It adds:

FY25 beat on top line and margin, with FY26 outlook a miss to consensus but largely in line with MRE. Despite an annualised tariff headwind of 75bps, FPH expect to achieve 65% gross margin target by FY28, ahead of our previous forecast.

Can Fisher & Paykel Healthcare shares keep rising?

The note reveals that Macquarie has retained its outperform rating on the company's shares with an improved price target of NZ$39.30. This implies potential upside of almost 13% for its NZ listed shares over the next 12 months.

Commenting on its outperform rating, the broker said:

We see the medium- to longer-term outlook as favourable, supported by uptake of new apps consumables (NHF, anaesthesia), OSA patient growth and increased utilisation from changing clinical practices.

The post Why does Macquarie think Fisher & Paykel shares are a buy? appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

According to a note out of Macquarie, its analysts have retained their outperform rating on this medical device company's shares with an improved price target of NZ$39.30 (A$36.51). This follows the release of Fisher & Paykel Healthcare's full year results last week, which beat both on the top line and with margins. And while the company's FY 2026 guidance fell short of expectations, the broker remains positive. Especially given that despite tariff headwinds, Fisher & Paykel Healthcare still expects to achieve its 65% gross margin target by FY 2028. This is ahead of what Macquarie was forecasting. Outside this, Macquarie sees the medium to longer-term outlook as favourable, supported by uptake of new app consumables, OSA patient growth, and increased utilisation from changing clinical practices. The Fisher & Paykel Healthcare share price is trading at $34.55 today.

Integral Diagnostics Ltd (ASX: IDX)

A note out of Bell Potter reveals that its analysts have retained their buy rating on this diagnostic imaging services provider's shares with an improved price target of $3.65. The broker is expecting Integral Diagnostics to deliver adjusted annual revenue growth of 34.4% to $631.2 million in FY 2025. Whereas adjusted operating EBITDA is expected to grow 35.7% to $124.2 million. The good news is that Bell Potter then expects this strong form to continue. It thinks the company is emerging with several tailwinds that could support double-digit earnings growth and ultimately a re-rating of its valuation. The Integral Diagnostics share price is fetching $2.45 at the time of writing.

Lynas Rare Earths Ltd (ASX: LYC)

Analysts at Morgan Stanley have retained their overweight rating and $10.00 price target on this rare earths producer's shares. According to the note, the broker is becoming increasingly positive on the company due to its potential to increase production thanks to the new Kalgoorlie facility. This bodes well for Lynas given its position as one of only two global rare earth supply producers outside of China. The Lynas share price is trading at $8.14 this afternoon.

The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.